<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calculator: International Prognostic Index for non-Hodgkin lymphoma in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calculator: International Prognostic Index for non-Hodgkin lymphoma in adults</h1>
<div class="utdArticleSection" id="topicContentCalculator"><div id="topicText">
<div id="mc3k">
<form action="" id="IPINHL_form" name="IPINHL_form" onreset="rrclr(); document.getElementById('inputchk').innerHTML=inputchktxt; " onsubmit="return false;">
<table cellpadding="4" cellspacing="0" summary="EBMcalc Table" width="100%">
<tbody><tr><td bgcolor="#eeeeee" width="1%"><br/></td>
<td align="left" bgcolor="#eeeeee">
<span class="medCalcFontTitleBox">

 
Calculator: International Prognostic Index for non-Hodgkin lymphoma in adults
</span></td></tr></tbody></table><br/> <br/>
<div id="calc_main">
<div id="calc_input">
<center>
<table cellpadding="3" cellspacing="0" summary="EBMcalc Table">
<tbody><tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate Age &gt;60 years old (1 point)" id="togel1" name="cc1" onclick="IPINHL_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel1');">Age &gt;60 years old (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate Serum lactate dehydrogenase concentration above normal (1 point)" id="togel2" name="cc2" onclick="IPINHL_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel2');">Serum lactate dehydrogenase concentration above normal (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate Ann Arbor stage III or IV (1 point)" id="togel3" name="cc3" onclick="IPINHL_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel3');">Ann Arbor stage III or IV (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate More than one extranodal disease site (1 point)" id="togel4" name="cc4" onclick="IPINHL_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel4');">More than one extranodal disease site (1 point)</span></td></tr>
<tr><td align="left" colspan="3"><span class="medCalcFontCCTabBold">ECOG performance scale </span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 0: Fully active; no performance restrictions (0 points)" id="togel5" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel5');"> Performance status 0: Fully active; no performance restrictions (0 points)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 1: Strenuous physical activity restricted; fully ambulatory and able to carry out light work (0 points)" id="togel6" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel6');"> Performance status 1: Strenuous physical activity restricted; fully ambulatory and able to carry out light work (0 points)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 2: Capable of all self-care but unable to carry out any work activities. Up and about &gt;50% of waking hours (1 point)" id="togel7" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel7');"> Performance status 2: Capable of all self-care but unable to carry out any work activities. Up and about &gt;50% of waking hours (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 3: Capable of only limited self-care; confined to bed or chair &gt;50% of waking hours (1 point)" id="togel8" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel8');"> Performance status 3: Capable of only limited self-care; confined to bed or chair &gt;50% of waking hours (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 4: Completely disabled; cannot carry out any self-care; totally confined to bed or chair (1 point)" id="togel9" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel9');"> Performance status 4: Completely disabled; cannot carry out any self-care; totally confined to bed or chair (1 point)</span></td></tr>
</tbody></table>
<span class="medCalcFontOne" id="inputchk"><br/> <br/><b>Important:</b> Inputs must be complete to perform calculation. <br/></span>
</center>
</div>
<br/> <br/>
<div id="calc_result">
<span class="medCalcFontCCTabBold">
Total criteria point count:
</span>
<input aria-label="This box holds the total criteria point count" aria-readonly="true" name="cctotal" size="6" type="text"/><br/> <br/>
<center><input name="reset" type="reset" value="Reset form"/> </center>
<br/> <br/>
<div aria-label="This table highlights the result When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:. No result is highlighted" id="rr1_tag" tabindex="0">
<table cellpadding="4" cellspacing="0" summary="EBMcalc Table" width="100%">
<tbody><tr><td bgcolor="#eeeeee" width="1%"><br/></td>
<td align="left" bgcolor="#eeeeee">
<span class="medCalcFontTitleBox">


When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:
</span></td></tr></tbody></table><br/> <br/>
</div>
<center>
<table border="1" cellpadding="4" cellspacing="0" summary="RRTable">
<tbody><tr id="rr1_1"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">0 to 1 point:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne">Low risk with 73% 5-year OS and 87% CR</span></td></tr>
<tr id="rr1_2"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">2 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> Low-intermediate risk with 51% 5-year OS and 67% CR</span></td></tr>
<tr id="rr1_3"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">3 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> High-intermediate risk with 43% 5-year OS and 55% CR</span></td></tr>
<tr id="rr1_4"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">4 to 5 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> High risk with 26% 5-year OS and 44% CR</span></td></tr>
</tbody></table>
</center>
<br/> <br/>
<br/> <br/>
<div aria-label="This table highlights the result When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:. No result is highlighted" id="rr2_tag" tabindex="0">
<table cellpadding="4" cellspacing="0" summary="EBMcalc Table" width="100%">
<tbody><tr><td bgcolor="#eeeeee" width="1%"><br/></td>
<td align="left" bgcolor="#eeeeee">
<span class="medCalcFontTitleBox">


When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:
</span></td></tr></tbody></table><br/> <br/>
</div>
<center>
<table border="1" cellpadding="4" cellspacing="0" summary="RRTable">
<tbody><tr id="rr2_5"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">0 to 1 point:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> EFS 81%, PFS 87%, and OS 91%</span></td></tr>
<tr id="rr2_6"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">2 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> EFS 69%, PFS 75%, and OS 81%</span></td></tr>
<tr id="rr2_7"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">3 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> EFS 53%, PFS 59%, and OS 65%</span></td></tr>
<tr id="rr2_8"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">4 to 5 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> EFS 50%, PFS 50%, and OS 59%</span></td></tr>
</tbody></table>
</center>
<br/> <br/>
</div>
</div>
<div id="calc_notes">
<span class="medCalcFontOneBold">Notes</span>
<ul class="medCalcFontOne">
<li><b>ECOG</b>: Eastern Cooperative Oncology Group; <b>NHL</b>: Non-Hodgkin lymphoma.</li>
</ul>
</div>
<br/> <br/>
<div id="calc_refs">
<span class="medCalcFontRef"><b>References</b></span>
<ol>
<li><span class="medCalcFontRef"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8141877" style="color: green; text-decoration: none;" target="_blank">The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive  non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987.</a></span></li>
<li><span class="medCalcFontRef"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20385988" style="color: green; text-decoration: none;" target="_blank">Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid  predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.  J Clin Oncol 2010; 28:2373. Erratum in: J Clin Oncol 2011; 29:779.</a></span></li>
<li><span class="medCalcFontRef"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7165009" style="color: green; text-decoration: none;" target="_blank">Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.  Am J Clin Oncol 1982; 5:649.</a></span></li>
</ol>
</div>
</form>
</div>
<span class="calculatorVendorId" id="T1678215873">
</span></div><div id="printDisclaimer">
<b>Only digits 0 to 9 and a single decimal point (".") are acceptable as numeric inputs. Attempted input of other characters into a numeric field may lead to an incorrect result.</b>
<p>
	Information on this page may not appear correctly if printed. </p>
</div>
<div id="disclaimerCalculator">
<div class="medCalcFontTwo">
<p class="header">Legal Notices and Disclaimer</p>
<p>
			All information contained in and produced by the EBMcalc system is provided
			for educational purposes only. This information should not be used for the diagnosis or treatment
			of any health problem or disease. 
			<b>THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.</b>
<a class="medCalcDisclaimerLink" href="/legal/ebmcalc-disclaimer">Click here for full notice and disclaimer.</a>
</p>
<p class="copy">EBMcalc is Copyright © 1998-2024 Foundation Internet Services, LLC</p>
</div>
</div><div id="topicVersionRevision">Topic 87307 Version 8.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
